Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

This phase 1/2 open-label study reports a planned update of the safety and efficacy of durvalumab in patients with locally advanced/metastatic urothelial carcinoma who had progressed on, were ineligible for, or refused prior chemotherapy.

from Cancer via ola Kala on Inoreader http://ift.tt/2vMuhaU
via IFTTT